1 |
Monami M, Vitale V, Ambrosio ML et al (2012) Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials. Adv Ther 29, 736-746
DOI
|
2 |
Gerstein HC, Bosch J, Dagenais GR et al (2012) Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 367, 319-328
DOI
|
3 |
Ben-Shlomo S, Zvibel I, Shnell M et al (2011) Glucagonlike peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase. J Hepatol 54, 1214-1223
DOI
|
4 |
Ding X, Saxena NK, Lin S, Gupta NA and Anania FA (2006) Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology 43, 173-181
DOI
|
5 |
Mells JE, Fu PP, Sharma S et al (2012) Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet. Am J Physiol Gastrointest Liver Physiol 302, G225-235
DOI
|
6 |
Armstrong MJ, Gaunt P, Aithal GP et al (2015) Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet [Epub ahead of print]
|
7 |
Wang XC, Gusdon AM, Liu H and Qu S (2014) Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation. World J Gastroenterol 20, 14821-14830
DOI
|
8 |
Aroor AR, Habibi J, Ford DA et al (2015) Dipeptidyl peptidase-4 inhibition ameliorates Western diet-induced hepatic steatosis and insulin resistance through hepatic lipid remodeling and modulation of hepatic mitochondrial function. Diabetes 64, 1988-2001
DOI
|
9 |
Kato H, Nagai Y, Ohta A et al (2015) Effect of sitagliptin on intrahepatic lipid content and body fat in patients with type 2 diabetes. Diabetes Res Clin Pract 109, 199-205
DOI
|
10 |
Macauley M, Hollingsworth KG, Smith FE et al (2015) Effect of vildagliptin on hepatic steatosis. J Clin Endocrinol Metab 100, 1578-1585
DOI
|
11 |
Scirica BM, Bhatt DL, Braunwald E et al (2013) Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369, 1317-1326
DOI
|
12 |
Ferrannini E, Muscelli E, Frascerra S et al (2014) Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 124, 499-508
DOI
|
13 |
Bolinder J, Ljunggren Ö, Johansson L et al (2014) Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab 16, 159-169
DOI
|
14 |
Yokono M, Takasu T, Hayashizaki Y et al (2014) SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats. Eur J Pharmacol 727, 66-74
DOI
|
15 |
Neumiller JJ (2014) Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. Drugs Context 3, 212-262
|
16 |
Bode B, Stenlöf K, Harris S et al (2015) Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes. Diabetes Obes Metab 17, 294-303
DOI
|
17 |
Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 373, 2117-2128
DOI
|
18 |
Erion DM, Lapworth A, Amor PA et al (2014) The hepatoselective glucokinase activator PF-04991532 ameliorates hyperglycemia without causing hepatic steatosis in diabetic rats. PLoS One 9, e97139
DOI
|
19 |
Pfefferkorn JA (2013) Strategies for the design of hepatoselective glucokinase activators to treat type 2 diabetes. Expert Opin Drug Discov 8, 319-330
DOI
|
20 |
Sammons MF and Lee EC (2015) Recent progress in the development of small-molecule glucagon receptor antagonists. Bioorg Med Chem Lett 25, 4057-4064
DOI
|
21 |
Guan HP, Yang X, Lu K et al (2015) Glucagon receptor antagonism induces increased cholesterol absorption. J Lipid Res 56, 2183-2195
DOI
|
22 |
Sazonov V, Maccubbin D, Sisk CM and Canner PL (2013) Effects of niacin on the incidence of new onset diabetes and cardiovascular events in patients with normoglycaemia and impaired fasting glucose. Int J Clin Pract 67, 297-302
DOI
|
23 |
McKenney J (2004) New perspectives on the use of niacin in the treatment of lipid disorders. Arch Intern Med 164, 697-705
DOI
|
24 |
Capuzzi DM, Morgan JM, Brusco OA Jr and Intenzo CM (2000) Niacin dosing: relationship to benefits and adverse effects. Curr Atheroscler Rep 2, 64-71
DOI
|
25 |
Drood JM, Zimetbaum PJ and Frishman WH (1991) Nicotinic-Acid for the Treatment of Hyperlipoproteinemia. J Clin Pharmacol 31, 641-650
DOI
|
26 |
Elam MB, Hunninghake DB, Davis KB et al (2000) Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial. JAMA 284, 1263-1270
DOI
|
27 |
Sugiyama S, Fukushima H, Kugiyama K et al (2007) Pravastatin improved glucose metabolism associated with increasing plasma adiponectin in patients with impaired glucose tolerance and coronary artery disease. Atherosclerosis 194, e43-51
DOI
|
28 |
Downs JR, Clearfield M, Weis S et al (1998) Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279, 1615-1622
DOI
|
29 |
Shepherd J, Cobbe SM, Ford I et al (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333, 1301-1307
DOI
|
30 |
McFarlane SI, Muniyappa R, Francisco R and Sowers JR (2002) Clinical review 145: Pleiotropic effects of statins: lipid reduction and beyond. J Clin Endocrinol Metab 87, 1451-1458
DOI
|
31 |
Preiss D, Seshasai SR, Welsh P et al (2011) Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 305, 2556-2564
DOI
|
32 |
Okamoto H, Yonemori F, Wakitani K, Minowa T, Maeda K and Shinkai H (2000) A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 406, 203-207
DOI
|
33 |
Sattar N, Preiss D, Murray HM et al (2010) Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 375, 735-742
DOI
|
34 |
Mullard A (2012) Cholesterol-lowering blockbuster candidates speed into Phase III trials. Nat Rev Drug Discov 11, 817-819
DOI
|
35 |
Roth EM, Taskinen MR, Ginsberg HN et al (2014) Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized Phase 3 trial. Int J Cardiol 176, 55-61
DOI
|
36 |
de Grooth GJ, Kuivenhoven JA, Stalenhoef AF et al (2002) Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans - A randomized phase II dose-response study. Circulation 105, 2159-2165
DOI
|
37 |
Nicholls SJ, Brewer HB, Kastelein JJ et al (2011) Effects of the CETP Inhibitor Evacetrapib Administered as Monotherapy or in Combination With Statins on HDL and LDL Cholesterol A Randomized Controlled Trial. JAMA 306, 2099-2109
DOI
|
38 |
Barter PJ, Rye KA, Tardif JC et al (2011) Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. Circulation 124, 555-562
DOI
|
39 |
Kharitonenkov A and Shanafelt AB (2009) FGF21: a novel prospect for the treatment of metabolic diseases. Curr Opin Investig Drugs 10, 359-364
|
40 |
Lin Z, Tian H, Lam KS et al (2013) Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice. Cell Metab 17, 779-789
DOI
|
41 |
Bernardo B, Lu M, Bandyopadhyay G et al (2015) FGF21 does not require interscapular brown adipose tissue and improves liver metabolic profile in animal models of obesity and insulin-resistance. Sci Rep 5, 11382
DOI
|
42 |
Gaich G, Chien JY, Fu H et al (2013) The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab 18, 333-340
DOI
|
43 |
Petersen KF, Dufour S, Hariri A et al (2010) Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N Engl J Med 362, 1082-1089
DOI
|
44 |
Petersen KF, Dufour S, Feng J et al (2006) Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men. Proc Natl Acad Sci U S A 103, 18273-18277
DOI
|
45 |
Lee HY, Birkenfeld AL, Jornayvaz FR et al (2011) Apolipoprotein CIII overexpressing mice are predisposed to diet-induced hepatic steatosis and hepatic insulin resistance. Hepatology 54, 1650-1660
DOI
|
46 |
Jørgensen AB, Frikke-Schmidt R, Nordestgaard BG and Tybjærg-Hansen A (2014) Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med 371, 32-41
DOI
|
47 |
Crosby J, Peloso GM, Auer PL et al (2014) Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med 371, 22-31
DOI
|
48 |
Timpson NJ, Walter K, Min JL et al (2014) A rare variant in APOC3 is associated with plasma triglyceride and VLDL levels in Europeans. Nat Commun 5, 4871
DOI
|
49 |
Cao J, Zhou Y, Peng H et al (2011) Targeting Acyl-CoA: diacylglycerol acyltransferase 1 (DGAT1) with small molecule inhibitors for the treatment of metabolic diseases. J Biol Chem 286, 41838-41851
DOI
|
50 |
Gaudet D, Brisson D, Tremblay K et al (2014) Targeting APOC3 in the familial chylomicronemia syndrome. N Engl J Med 371, 2200-2206
DOI
|
51 |
Chen HC and Farese RV Jr (2005) Inhibition of triglyceride synthesis as a treatment strategy for obesity: lessons from DGAT1-deficient mice. Arterioscler Thromb Vasc Biol 25, 482-486
DOI
|
52 |
Yamamoto T, Yamaguchi H, Miki H et al (2010) Coenzyme A: diacylglycerol acyltransferase 1 inhibitor ameliorates obesity, liver steatosis, and lipid metabolism abnormality in KKAy mice fed high-fat or high-carbohydrate diets. Eur J Pharmacol 640, 243-249
DOI
|
53 |
Choi CS1, Savage DB, Kulkarni A et al (2007) Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance. J Biol Chem 282, 22678-22688
DOI
|
54 |
Denison H, Nilsson C, Kujacic M et al (2013) Proof of mechanism for the DGAT1 inhibitor AZD7687: results from a first-time-in-human single-dose study. Diabetes Obes Metab 15, 136-143
DOI
|
55 |
Wierzbicki AS, Hardman TC and Viljoen A (2012) New lipid-lowering drugs: an update. Int J Clin Pract 66, 270-280
DOI
|
56 |
Lee YJ, Ko EH, Kim JE et al (2012) Nuclear receptor PPARgamma-regulated monoacylglycerol O-acyltransferase 1 (MGAT1) expression is responsible for the lipid accumulation in diet-induced hepatic steatosis. Proc Natl Acad Sci U S A 109, 13656-13661
DOI
|
57 |
Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U and Shaw JE (2014) Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract 103, 137-149
DOI
|
58 |
Hall AM, Soufi N, Chambers KT et al (2014) Abrogating monoacylglycerol acyltransferase activity in liver improves glucose tolerance and hepatic insulin signaling in obese mice. Diabetes 63, 2284-2296
DOI
|
59 |
Hall AM, Kou K, Chen Z et al (2012) Evidence for regulated monoacylglycerol acyltransferase expression and activity in human liver. J Lipid Res 53, 990-999
DOI
|
60 |
Zimmet P, Alberti KG and Shaw J (2001) Global and societal implications of the diabetes epidemic. Nature 414, 782-787
DOI
|
61 |
Roger VL, Go AS, Lloyd-Jones DM et al (2012) Heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation 125, e2-e220
DOI
|
62 |
UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352, 837-853
DOI
|
63 |
Bonora E, Formentini G, Calcaterra F et al (2002) HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study. Diabetes Care 25, 1135-1141
DOI
|
64 |
Wajchenberg BL (2007) beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 28, 187-218
DOI
|
65 |
Rothman DL, Shulman RG and Shulman GI (1992) 31P nuclear magnetic resonance measurements of muscle glucose-6-phosphate. Evidence for reduced insulin-dependent muscle glucose transport or phosphorylation activity in non-insulin-dependent diabetes mellitus. J Clin Invest 89, 1069-1075
DOI
|
66 |
Shulman GI, Rothman DL, Jue T, Stein P, DeFronzo RA and Shulman RG (1990) Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by 13C nuclear magnetic resonance spectroscopy. N Engl J Med 322, 223-228
DOI
|
67 |
Hwang JH, Perseghin G, Rothman DL et al (1995) Impaired net hepatic glycogen synthesis in insulin-dependent diabetic subjects during mixed meal ingestion. A 13C nuclear magnetic resonance spectroscopy study. J Clin Invest 95, 783-787
DOI
|
68 |
DeFronzo RA, Ferrannini E and Simonson DC (1989) Simonson, Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake. Metabolism 38, 387-395
DOI
|
69 |
Landau BR, Wahren J, Chandramouli V, Schumann WC, Ekberg K and Kalhan SC (1996) Contributions of gluconeogenesis to glucose production in the fasted state. J Clin Invest 98, 378-385
DOI
|
70 |
DeFronzo RA and Tripathy D (2009) Tripathy, Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care 32, S157-S163
DOI
|
71 |
Perry RJ, Camporez JP, Kursawe R et al (2015) Hepatic acetyl CoA links adipose tissue inflammation to hepatic insulin resistance and type 2 diabetes. Cell, 160, 745-758
DOI
|
72 |
Wu L and Parhofer KG (2014) Diabetic dyslipidemia. Metabolism 63, 1469-1479
DOI
|
73 |
Reaven GM (1988) Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37, 1595-1607
DOI
|
74 |
Samuel VT and Shulman GI (2012) Mechanisms for insulin resistance: common threads and missing links. Cell 148, 852-871
DOI
|
75 |
Chaurasia B and Summers SA (2015) Ceramides - Lipotoxic Inducers of Metabolic Disorders. Trends Endocrinol Metab 26, 538-550
DOI
|
76 |
Samuel VT, Liu ZX, Qu X et al (2004) Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem 279, 32345-32353
DOI
|
77 |
Magkos F, Su X, Bradley D et al (2012) Intrahepatic diacylglycerol content is associated with hepatic insulin resistance in obese subjects. Gastroenterology 142, 1444-1446 e2
DOI
|
78 |
Haus JM, Kashyap SR, Kasumov T et al (2009) Plasma ceramides are elevated in obese subjects with type 2 diabetes and correlate with the severity of insulin resistance. Diabetes 58, 337-343
DOI
|
79 |
Jurczak MJ, Lee AH, Jornayvaz FR et al (2012) Dissociation of inositol-requiring enzyme (IRE1alpha)-mediated c-Jun N-terminal kinase activation from hepatic insulin resistance in conditional X-box-binding protein-1 (XBP1) knock-out mice. J Biol Chem 287, 2558-2567
DOI
|
80 |
Lee SY, Hong IK, Kim BR et al (2015) Activation of sphingosine kinase 2 by endoplasmic reticulum stress ameliorates hepatic steatosis and insulin resistance in mice. Hepatology 62, 135-146
DOI
|
81 |
Adams JM 2nd, Pratipanawatr T, Berria R et al (2004) Ceramide content is increased in skeletal muscle from obese insulin-resistant humans. Diabetes 53, 25-31
DOI
|
82 |
Mooradian AD (2009) Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab 5, 150-159
DOI
|
83 |
Semple RK, Sleigh A, Murgatroyd PR et al (2009) Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis. J Clin Invest 119, 315-322
|
84 |
Rader DJ (2007) Effect of insulin resistance, dyslipidemia, and intra-abdominal adiposity on the development of cardiovascular disease and diabetes mellitus. Am J Med 120, S12-S18
DOI
|
85 |
Adiels M, Olofsson SO, Taskinen MR and Borén J (2008) Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol 28, 1225-1236
DOI
|
86 |
Bang KB and Cho YK (2015) Comorbidities and Metabolic Derangement of NAFLD. J Lifestyle Med 5, 7-13
DOI
|
87 |
American Diabetes Association (2009) Standards of medical care in diabetes--2009. Diabetes Care 32, S13-S61
DOI
|
88 |
Koo SH (2013) Nonalcoholic fatty liver disease: molecular mechanisms for the hepatic steatosis. Clin Mol Hepatol 19, 210-215
DOI
|
89 |
Athyros VG, Tziomalos K, Katsiki N, Doumas M, Karagiannis A and Mikhailidis DP (2015) Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update. World J Gastroenterol 21, 6820-6834
DOI
|
90 |
Williams CD, Stengel J, Asike MI et al (2011) Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 140, 124-131
DOI
|
91 |
Klip A and Leiter LA (1990) Cellular mechanism of action of metformin. Diabetes Care 13, 696-704
DOI
|
92 |
Stumvoll M, Nurjhan N, Perriello G, Dailey G and Gerich JE (1995) Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 333, 550-554
DOI
|
93 |
Kim YD, Park KG, Lee YS et al (2008) Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP. Diabetes 57, 306-314
DOI
|
94 |
Zhou G, Myers R, Li Y et al (2001) Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108, 1167-1174
DOI
|
95 |
Wulffelé MG, Kooy A, de Zeeuw D, Stehouwer CD and Gansevoort RT (2004) The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review. J Intern Med 256, 1-14
DOI
|
96 |
Soccio RE, Chen ER and Lazar MA (2014) Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes. Cell Metab 20, 573-591
DOI
|
97 |
Shields WW, Thompson KE, Grice GA, Harrison SA and Coyle WJ (2009) The Effect of Metformin and Standard Therapy versus Standard Therapy alone in Nondiabetic Patients with Insulin Resistance and Nonalcoholic Steatohepatitis (NASH): A Pilot Trial. Therap Adv Gastroenterol 2, 157-163
DOI
|
98 |
Madiraju AK, Erion DM, Rahimi Y et al (2014) Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature 510, 542-546
DOI
|
99 |
Fujita T, Sugiyama Y, Taketomi S et al (1983) Reduction of insulin resistance in obese and/or diabetic animals by 5-[4-(1-methylcycloheylmethoxy)benzyl]-thiazolidine-2,4-dione (ADD-3878, U-63,287, ciglitazone), a new antidiabetic agent. Diabetes 32, 804-810
DOI
|
100 |
Chao L, Marcus-Samuels B, Mason MM et al (2000) Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones. J Clin Invest 106, 1221-1228
DOI
|
101 |
Ohno H, Shinoda K, Spiegelman BM and Kajimura S (2012) PPARgamma agonists induce a white-to-brown fat conversion through stabilization of PRDM16 protein. Cell Metab 15, 395-404
DOI
|
102 |
Kahn SE, Haffner SM, Heise MA et al (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355, 2427-2443
DOI
|
103 |
Belfort R, Harrison SA, Brown K et al (2006) A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 355, 2297-2307
DOI
|
104 |
Sanyal AJ, Chalasani N, Kowdley KV et al (2010) Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 362, 1675-1685
DOI
|
105 |
Colca JR, VanderLugt JT, Adams WJ et al (2013) Clinical proof-of-concept study with MSDC-0160, a prototype mTOT-modulating insulin sensitizer. Clin Pharmacol Ther 93, 352-359
DOI
|
106 |
Ratziu V, Giral P, Jacqueminet S et al (2008) Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology 135, 100-110
DOI
|
107 |
Cariou B, Charbonnel B and Staels B (2012) Thiazolidinediones and PPARgamma agonists: time for a reassessment. Trends Endocrinol Metab 23, 205-215
DOI
|
108 |
Gray LR, Sultana MR, Rauckhorst AJ et al (2015) Hepatic Mitochondrial Pyruvate Carrier 1 Is Required for Efficient Regulation of Gluconeogenesis and Whole-Body Glucose Homeostasis. Cell Metab 22, 669-681
DOI
|
109 |
Kramer W, Müller G and Geisen K (1996) Characterization of the molecular mode of action of the sulfonylurea, glimepiride, at beta-cells. Horm Metab Res 28, 464-468
DOI
|
110 |
DeFronzo RA and Simonson DC (1984) Oral sulfonylurea agents suppress hepatic glucose production in non-insulin-dependent diabetic individuals. Diabetes Care 7, 72-80
DOI
|
111 |
Taskinen MR, Beltz WF, Harper I et al (1986) Effects of NIDDM on very-low-density lipoprotein triglyceride and apolipoprotein B metabolism. Studies before and after sulfonylurea therapy. Diabetes 35, 1268-1277
DOI
|
112 |
Howard BV, Xiaoren P, Harper I, Foley JE, Cheung MC and Taskinen MR (1985) Effect of sulfonylurea therapy on plasma lipids and high-density lipoprotein composition in non-insulin-dependent diabetes mellitus. Am J Med 79, 78-85
DOI
|